JP2004529161A - 縮合複素環式化合物 - Google Patents

縮合複素環式化合物 Download PDF

Info

Publication number
JP2004529161A
JP2004529161A JP2002586869A JP2002586869A JP2004529161A JP 2004529161 A JP2004529161 A JP 2004529161A JP 2002586869 A JP2002586869 A JP 2002586869A JP 2002586869 A JP2002586869 A JP 2002586869A JP 2004529161 A JP2004529161 A JP 2004529161A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydrogen
group
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002586869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529161A5 (enExample
Inventor
チェン，シャオキー
ダイ，カン
ファン，ピンチェン
ホワン，シュウギ
リ，レピン
ミハリク，ジェフリー，トーマス
Original Assignee
トゥラリック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥラリック インコーポレイテッド filed Critical トゥラリック インコーポレイテッド
Publication of JP2004529161A publication Critical patent/JP2004529161A/ja
Publication of JP2004529161A5 publication Critical patent/JP2004529161A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002586869A 2001-05-04 2002-05-03 縮合複素環式化合物 Pending JP2004529161A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28866501P 2001-05-04 2001-05-04
PCT/US2002/013856 WO2002089729A2 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Publications (2)

Publication Number Publication Date
JP2004529161A true JP2004529161A (ja) 2004-09-24
JP2004529161A5 JP2004529161A5 (enExample) 2005-12-22

Family

ID=23108101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002586869A Pending JP2004529161A (ja) 2001-05-04 2002-05-03 縮合複素環式化合物

Country Status (9)

Country Link
US (1) US6858619B2 (enExample)
EP (1) EP1392298B1 (enExample)
JP (1) JP2004529161A (enExample)
AT (1) ATE422887T1 (enExample)
AU (1) AU2002305323A1 (enExample)
CA (1) CA2446351A1 (enExample)
DE (1) DE60231202D1 (enExample)
ES (1) ES2319619T3 (enExample)
WO (1) WO2002089729A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
CA2446351A1 (en) 2001-05-04 2002-11-14 Tularik Inc. Fused heterocyclic compounds
WO2003045920A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
EP1562943A1 (en) * 2002-11-06 2005-08-17 Amgen Inc. Fused heterocyclic compounds
AU2004209505B2 (en) * 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2322965T3 (es) 2005-09-30 2009-07-02 F. Hoffmann-La Roche Ag Derivados de indano como antagonistas de receptores de mch.
CN101384555A (zh) 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基二氢异喹啉酮类、其制备方法以及其作为药物的用途
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
US8575186B2 (en) * 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013135803A1 (en) * 2012-03-16 2013-09-19 Glucox Biotech Ab Thiophene-based compounds exhibiting nox4 inhibitory activity and use thereof in therapy
JP6274384B2 (ja) * 2012-04-27 2018-02-07 Nok株式会社 メタルガスケット及びその製造方法
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
DE69232484T2 (de) * 1991-07-05 2002-10-31 Smithkline Beecham S.P.A., Baranzate Di Bollate Hydroisochinolinderivate
FI942499A7 (fi) 1992-09-29 1994-07-27 Toray Industries Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
DE69822937T2 (de) 1997-01-16 2004-08-12 Toray Industries, Inc. Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
US6618416B1 (en) 1998-10-07 2003-09-09 Sharp Kabushiki Kaisha Semiconductor laser
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
CN1341123A (zh) 1999-02-19 2002-03-20 武田药品工业株式会社 新型g蛋白偶联型受体蛋白及其dna
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
EP1246847A2 (en) 2000-07-05 2002-10-09 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
AU783403B2 (en) 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US7273710B2 (en) 2000-07-05 2007-09-25 Takeda Pharmaceutical Company Limited Method for screening MCH receptor antagonist/agonist
EP1366030A2 (en) 2000-07-06 2003-12-03 Neurogen Corporation Melanin concentrating hormone receptor ligands
AP2001002307A0 (en) 2000-10-20 2001-12-31 Pfizer Prod Inc B3 adrenergic receptor agonists and uses thereof.
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
ATE302185T1 (de) 2000-12-22 2005-09-15 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
AU2002247367B2 (en) 2001-03-21 2005-10-27 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
MXPA03009353A (es) 2001-04-12 2004-02-12 Pharmacopeia Inc Aril y biaril piperidinas utilizadas como antagonistas de mch.
CA2446351A1 (en) 2001-05-04 2002-11-14 Tularik Inc. Fused heterocyclic compounds
CN1703401A (zh) 2001-05-22 2005-11-30 神经原公司 黑色素浓集激素受体的配体:取代的1－苄基－4－芳基哌嗪类似物

Also Published As

Publication number Publication date
ES2319619T3 (es) 2009-05-11
EP1392298A2 (en) 2004-03-03
WO2002089729A3 (en) 2003-04-03
EP1392298B1 (en) 2009-02-18
US6858619B2 (en) 2005-02-22
ATE422887T1 (de) 2009-03-15
AU2002305323A1 (en) 2002-11-18
DE60231202D1 (de) 2009-04-02
WO2002089729A2 (en) 2002-11-14
EP1392298A4 (en) 2005-05-25
CA2446351A1 (en) 2002-11-14
US20030023085A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
JP2004529161A (ja) 縮合複素環式化合物
JP2006510598A (ja) ピペリジン誘導体
TW322478B (enExample)
KR20180086247A (ko) 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
CN106715435B (zh) 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物
Sniecikowska et al. From receptor selectivity to functional selectivity: the rise of biased agonism in 5-HT1A receptor drug discovery
US20080058365A1 (en) Fused heterocyclic compounds
CN106661002A (zh) 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的任选稠合的、经杂环基取代的嘧啶衍生物
CN102170883A (zh) 可用作蛋白激酶抑制剂的化合物
JP2021520340A (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
JP2000516957A (ja) 置換されている１，２，３，４―テトラヒドロ―２―ジベンゾフランアミン類および２―アミノシクロヘプタ［ｂ］ベンゾフラン類
US6809104B2 (en) Fused heterocyclic compounds
US20070135425A1 (en) Fused heterocyclic compounds
US7030122B2 (en) 1,4-disubstituted piperazine ligands for neurotransmitter receptors
Fulton Challenges in the Discovery and Optimization of MGLU2/4 Heterodimer Positive Allosteric Modulators and Total Synthesis of Epi-and Pericoannosin A

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811